Phase II propensity-matched controlled trial evaluating metformin as an adjunct to neo-adjuvant, concomitant, and adjuvant temozolomide and hypofractionated-accelerated radiotherapy (M-HART) in glioblastoma patients (NCT02780024).

George Shenouda, Luís Souhami, Jeffery A. Hall et al.|Journal of Clinical Oncology|2025

Cited by 3